Table 1 Clinical features
From: The JAK2 pathway is activated in idiopathic pulmonary fibrosis
Control donor subjects (n = 10) | IPF patients (n = 12) | |
|---|---|---|
Age (yr) | 57 [38–65] | 66 [58–75] |
Sex (M/F) | 6/4 | 9/3 |
Smoking | ||
Never smoked/Smokers | 3/7 | 1/11 |
Pack-year | 25 [0–28] | 26.3 [11–34] |
FEV1, pred | ND | 72.2 [56–96] |
FVC, % pred | ND | 62.2 [55–68] |
TLC, % pred | ND | 73.5 [45–89] |
DLco, % pred | ND | 42.1 [31–51] |
Ground glass % | 0 | 25 [20–39] |
Honeycombing % | 0 | 35 [25–40] |
NAC (y/n) | 0/10 | 8/4 |
Pirfenidone (y/n) | 0/10 | 4/8 |